CAMEO+ eventCORPORATE2026-05-03馃嚭馃嚫
UCB to acquire Candid Therapeutics, expanding immunology T-cell pipeline
source: UCB -> target: Candid Therapeutics
On 2026-05-03, UCB announced a definitive agreement to acquire Candid Therapeutics, a privately held clinical-stage biotechnology company. The deal is intended to expand UCB鈥檚 immunology pipeline, especially in novel T-cell engagers for autoimmune and inflammatory diseases.
0.24Significance4.0Magnitude0.3Systemic0.4Market1Articles
Location
San DiegoCaliforniaNorth AmericaUnited StatesNorth America32.716, -117.161
Story Links